香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年9月29日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 证券代码：688366 证券简称：昊海生科 公告编号：2025-043 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司股 東減持股份結果公告》， ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-043 减持计划的实施结果情况 公司于 2025 年 6 月 25 日披露了《上海昊海生物科技股份有限公司股东减持 股份计划公告》（公告编号：2025-032），楼国梁先生因自身资金需要，计划自该 公告披露之日起 3 个交易日后 3 个月内，通过集中竞价和大宗交易方式合计减持 不超过 1,500,000 股的公司股份，占减持计划披露时公司总股本 233,193,695 股的 比例不超过 0.6432%，其中，通过集中竞价方式减持不超过 1,500,000 股，通过 大宗交易方式减持不超过 1,500,000 股。减持价格将根据二级市场价格确定。 公司于 2025 年 9 月 29 日收到楼国梁先生出具的《关于股份减持结果的告知 函》，其本次股份减持计划时间区间届满。截至 2025 年 9 月 29 日，楼国梁先生 已通过集中竞价的方式累计减持公司股份 1,491,447 股，占目前公司总股本 232,581,095 股的 0.6413%。现将具体情况公告如下： 1 上海昊海生物科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股 ...

Core Viewpoint - Haohai Biological Technology (688366.SH) announced the completion of a share reduction plan by Mr. Lou Guoliang, who has reduced his holdings in the company [1] Summary by Relevant Sections - Share Reduction Details - Mr. Lou Guoliang has reduced his shareholding by a total of 1.4914 million shares, which accounts for 0.6413% of the company's total share capital as of September 29, 2025 [1]

Group 1 - The 2025 World Design Capital Conference (WDCC2025) opened on September 25 in Shanghai, showcasing nearly 500 participating brands and over 3,000 exhibits within an exhibition space of approximately 15,000 square meters, with international brands accounting for about 20% and emerging brands for about 60% [1] - The MG brand, known for its sporty DNA and unique design, presented electric sports cars inspired by racing helmets, embodying a blend of speed, passion, and youthfulness, and aims to transform into a "mobile trendy toy" that is interactive and relatable [4][3] - The MANITO OASIS installation, created by the Canadian silk brand MANITO, emphasizes a nature-inspired design, capturing the beauty of the natural world and promoting the brand's philosophy of a natural lifestyle [6][5] Group 2 - The Shanghai-based medical company Haohai Biological Technology showcased an immersive art exhibition titled "Renaissance of Cells," breaking traditional display methods and allowing audiences to experience a molecular network beyond human scale, highlighting the revival of cells [8][7] - The installation features a giant transparent sphere connected by fine metal rods, resembling a molecular framework, and transforms laboratory scenes into an artistic representation of a dynamic life theater, enabling viewers to glimpse the universe from a microscopic perspective [8]

FF305 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年9月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括 ...

Group 1 - The company, Haohai Biological Technology (06826), announced a share buyback on September 24, 2025, spending HKD 1.4123 million to repurchase 51,900 shares [1] - The buyback price ranged from HKD 26.92 to HKD 27.32 per share [1]

Core Viewpoint - Haohai Biological Technology (06826) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company plans to repurchase 51,900 shares at a total cost of HKD 1.4123 million [1] - The buyback price ranges from HKD 26.92 to HKD 27.32 per share [1]

Core Viewpoint - Haohai Biological Technology (06826.HK) announced a share buyback on September 24, spending HKD 1.412 million to repurchase 52,000 shares [1] Group 1 - The company executed a buyback of 52,000 shares [1] - The total expenditure for the buyback was HKD 1.412 million [1]

表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 呈交日期： 2025年9月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變 ...

Core Viewpoint - The beauty and medical aesthetics industry is experiencing a stark contrast, with medical aesthetic companies facing significant pressure while domestic beauty brands are actively entering the medical aesthetics market [3][4][5] Medical Aesthetics Industry Performance - Among 22 medical aesthetics companies, 14 reported a year-on-year decline in revenue during the first half of the year, with "medical aesthetics trio" member Aimeike experiencing a decline exceeding 20% [4][5] - The medical aesthetics market has been growing rapidly, with a projected market size of nearly 3,700 billion by 2025, growing at an annual rate of 17.4% since 2020 [4] Competitive Landscape - The medical aesthetics industry is facing intensified competition, particularly in upstream raw materials and equipment, leading to declining revenues for companies like Aimeike and Haohai Biological [6][7] - The consumer market is becoming more rational, with 73% of mid-to-high-income consumers planning to reduce or maintain their medical aesthetics spending in 2024 compared to 2023 [7] Domestic Beauty Brands' Strategies - Over 20 domestic beauty companies are entering the medical aesthetics sector, with brands like Naturating and Youshiyan launching new products aimed at the medical aesthetics market [10][12] - Baijuerling has launched three medical aesthetics brands, focusing on injection regeneration, post-operative care, and medical equipment, indicating a comprehensive approach to the medical aesthetics industry [16][20] Market Challenges and Opportunities - The market for medical aesthetics is becoming increasingly competitive, with established brands like 可复美 and 薇诺娜 already dominating the "medical device" segment, making differentiation a key challenge for new entrants [22][25] - Despite the challenges, the structural adjustment in the medical aesthetics industry presents opportunities for collaboration and innovation, as companies explore new product offerings and partnerships [25][27]